Enzyme by Design

Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. Using protein engineering expertise, EbD has created protein molecules targeting pediatric cancer as well as notoriously difficult to treat cancers like acute myeloid leukemia, pancreatic, liver, and ovarian cancers. The company's clinical strategy incorporates well-known drug mechanisms of action and patient genomic and epigenetic markers to ensure that only those patients likely to benefit greatly from their biologics will receive them. EbD's passion for developing cancer drugs that combat cancer without collateral damage addresses the critical need for improved cancer treatment options. Founded in 2017, the startup operates in the Biotechnology and Health Care industries. With a compelling slogan emphasizing their dedication to patient safety and innovative approach to cancer treatment, Enzyme by Design presents a promising investment opportunity.